Iindaba zenkampani
-
Iindaba Ezivuyisayo | I-JYMed's Liraglutide API iFumana iSatifikethi seWC
Ngomhla we-12 ku-Okthobha, ngo-2024, i-JYMed's Liraglutide API yafumana isatifikethi esiBhaliweyo sokuQinisekisa (WC), esiphawula inyathelo elibalulekileyo ekuthumeleni ngempumelelo i-API kwimarike ye-EU. I-WC (iSiqinisekiso esiBhaliweyo)...Funda ngokugqithisileyo -
Sivuyisana ne-JYMed's Tirzepatide igqibezela ukufayila kwe-US-DMF
I-JYMed Technology Co., Ltd. iyavuya ukwazisa ukuba imveliso yayo, i-Tirzepatide, igqibe ngempumelelo ukubhaliswa kweFayile eyi-Drug Master (DMF) kunye ne-US FDA (Inombolo ye-DMF: 040115) kwaye ifumene i-Acknowl ye-FDA ...Funda ngokugqithisileyo -
I-JYMed Peptide ikumema ukuba uzimase uMboniso weZithako zezithambiso eKorea ka-2024
Indawo: Korea International Exhibition Centre Umhla: Julayi 24-26, 2024 Ixesha: 10:00 AM - 5:00 PM Idilesi: I-COEX Exhibition Centre Hall C, 513 Yeongdong-daero, Gangnam-gu, Seoul, 06164 In-cosmetics liqela elikhokelayo lokunyamekela lobuqu kwiqela lomboniso wamazwe ngamazwe ...Funda ngokugqithisileyo
